• Strategic Partnership Aims to Advance Proteomics CRO Services
    Biognosys is a leading provider of unbiased proteomics CRO services.

Mass Spectrometry & Spectroscopy

Strategic Partnership Aims to Advance Proteomics CRO Services

Jan 12 2023

Bruker Corporation and Switzerland-based Biognosys AG have announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys.

Co-Founder and CEO Dr Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company. Going forward, Biognosys’ biomarker and biopharma customers will benefit from additional services and footprint in the US. Biognosys will access Bruker’s leading 4D proteomics timsTOF technology for deeper, unbiased high-precision proteomics that is not impaired by epitope cross-reactivity - all with higher throughput and excellent reproducibility.

Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers in uncovering connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology. In particular, the Biognosys TrueTarget™, TrueDiscovery™, and TrueSignature™ research service solutions provide deep, peptide-level proteome insights for drug discovery and development:

The Bruker-Biognosys collaboration is expected to create unique synergies between Biognosys’ versatile portfolio of proprietary proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.

Dr Oliver Rinner, CEO and Co-Founder of Biognosys, commented: "We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development. We have worked closely with Bruker to support dia-PASEF® high-throughput, deeper proteomics methods within our Spectronaut® software. Biognosys remains committed to maintaining Spectronaut® as a high-performance vendor-agnostic proteomics software. We plan to establish our US CRO lab in Massachusetts using the timsTOF platform, so that our customers can benefit from multiple MS technologies.”

Dr Rohan Thakur, President of the Bruker Life-Science Mass Spectrometry division, said: “We are delighted to partner with Biognosys to expand our CRO business in the US. We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development. With the rapid scientific acceptance of dia-PASEF workflows, our partnership offers a unique combination of proteomics applications and data-science expertise, which can benefit more biopharma and diagnostics companies in using unbiased proteomics for decision-making.”


Digital Edition

Lab Asia 29.6 Dec

December 2022

In This Edition Chromatography - Optimising Viral Vector Purification Strategies with Multimodal Chromatography - Key UHPLC Characteristics Required for High throughput LC-MS - New Low Volu...

View all digital editions

Events

Arab Health

Jan 30 2023 Dubai, UAE

Nano Tech 2023

Feb 01 2023 Tokyo, Japan

Medlab Middle East

Feb 06 2023 Dubai, UAE

FILTECH

Feb 14 2023 Cologne, Germany

View all events